Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...
New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations...
MD Anderson achieves sixth Magnet designation in recognition of nursing excellence
The American Nurses Credentialing Center (ANCC) Magnet Recognition Program is the highest honor of excellence in nursing
MD Anderson achieved...
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with differential benefit from CD19 CAR T cell therapy
Study points to opportunities for alternative approaches to treat patients who do not benefit from CAR T cell therapies
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...
MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for...
Mailed self-collection HPV tests boost cervical cancer screening rates
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes...
ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients...
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib,...
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...
New biomarker may guide best use of KRAS inhibitors in lung cancer
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib...
ASCO: MD Anderson’s Christopher Flowers honored for teaching and mentorship
Christopher Flowers, M.D., division head of Cancer Medicine and chair of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...
UT MD Anderson and Texas Children’s Hospital announce $150 million gift from Kinder Foundation to launch Kinder Children’s Cancer Center
The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital today announced a $150 million gift from Kinder Foundation...
AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress...
AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
...
...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other DNA...
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1...
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of Texas...
AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/...
MD Anderson breaks ground on new Sugar Land location
The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range...
Surgery may not be necessary to treat invasive breast cancer
Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant...
Two MD Anderson researchers elected AAAS Fellows
In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph.D., from The...
MD Anderson names Jeffrey E. Lee, M.D., Chief Medical Executive
The University of Texas MD Anderson Cancer Center today announced that Jeffrey E. Lee, M.D., an internationally regarded leader in the...
MD Anderson and UT Austin launch joint initiative to advance breakthroughs in cancer research
The University of Texas MD Anderson Cancer Center and The University of Texas at Austin have launched a joint initiative, the Collaborative...
MD Anderson Research Highlights for February 26, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Public Notice of Scheduled Site Visit to MD Anderson by ANCC Magnet Recognition Program Appraisers
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
What is Magnet and why is Magnet important?
ANCC Magnet...
MD Anderson researchers develop novel antibody-toxin conjugate
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate...
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer
The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a transformational collaboration dedicated...
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of...
Scientists find new biomarker that predicts cancer aggressiveness
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer...
MD Anderson Research Highlights for February 10, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
ABSTRACT: 16
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment...
MD Anderson Research Highlights for January 22, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ExxonMobil donates $10 million to fund MD Anderson-led Be Well™ Beaumont initiative
In an effort to improve public health and reduce cancer risk in East Texas, leaders in Beaumont are working with The University of Texas...
Chances of quitting smoking improve with integrated care, including medication and counseling
Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and...
MD Anderson Research Highlights for January 9, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the...